Opus Genetics (IRD) Cash & Equivalents (2010 - 2026)

Opus Genetics (IRD) has 17 years of Cash & Equivalents data on file, last reported at $60.0 million in Q1 2026.

• On a quarterly basis, Cash & Equivalents rose 43.57% year-over-year to $60.0 million in Q1 2026; TTM through Mar 2026 was $60.0 million, a 43.57% increase from a year earlier, with the FY2025 full-year figure at $45.1 million, up 48.71% from the prior year.
• Cash & Equivalents for Q1 2026 stood at $60.0 million, up from $45.1 million in the prior quarter.
• Over the last five years, Cash & Equivalents for IRD reached as high as $60.0 million in Q1 2026 and fell as low as $13.9 million in Q3 2022.
• Historically, Cash & Equivalents has averaged $37.1 million across 5 years, with a median of $40.0 million in 2023.
• Across the five-year window, Cash & Equivalents jumped 205.67% in 2023 and plunged 39.96% in 2024, its largest moves.
• Year by year, Cash & Equivalents stood at $42.6 million in 2022, then rose by 18.45% to $50.5 million in 2023, then slumped by 39.96% to $30.3 million in 2024, then jumped by 48.71% to $45.1 million in 2025, then soared by 33.06% to $60.0 million in 2026.
• Per Business Quant data, the three most recent Cash & Equivalents figures were $60.0 million in Q1 2026, $45.1 million in Q4 2025, and $30.8 million in Q3 2025.